Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOiL-INFLAMe: Intravenous Fish Oil Emulsion in Critically Ill Patients
NCT07883447Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of eicosapentaenoic acid + docosahexaenoic acid in critical illness (3 arms). Primary endpoint: Change in blood interleukin-6 concentration at Day 4. Started Jul 2026; status: recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT07883447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883447.